Published in J Clin Hypertens (Greenwich) on December 01, 2007
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet (2010) 9.20
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension (2008) 6.96
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03
Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation (2008) 5.26
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.21
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA (2005) 3.89
Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study. Ann Intern Med (2013) 2.74
Use of diuretics in patients with hypertension. N Engl J Med (2009) 2.58
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation (2008) 2.51
Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study. Ann Intern Med (2015) 2.42
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2012) 2.42
Diabetes and hypertension: the bad companions. Lancet (2012) 2.10
Comments on progress, medical care, and the overuse of technology. J Clin Hypertens (Greenwich) (2005) 2.04
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med (2009) 2.02
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med (2005) 1.99
Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int (2011) 1.91
Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care (2013) 1.71
Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use. Arch Intern Med (2010) 1.64
The choice of thiazide diuretics: why chlorthalidone may replace hydrochlorothiazide. Hypertension (2009) 1.62
Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcomes (2012) 1.59
Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J Gen Intern Med (2010) 1.57
Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care (2012) 1.55
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation (2011) 1.52
Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension (2008) 1.46
Acupuncture for hypertension: can 2500 years come to an end? Hypertension (2006) 1.46
Impact of Non-Adherence on Renal and Cardiovascular Outcomes in US Veterans. Am J Nephrol (2015) 1.42
Primary aldosteronism: an update on screening, diagnosis and treatment. J Hypertens (2008) 1.42
Comments on the present status and future directions of postgraduate medical education. J Clin Hypertens (Greenwich) (2005) 1.40
New-onset diabetes in the hypertension treatment trials: a point of view. J Clin Hypertens (Greenwich) (2004) 1.39
Hypertension and heart failure. Roundtable discussion. J Clin Hypertens (Greenwich) (2004) 1.38
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. Am Heart J (2007) 1.33
Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone. Curr Control Trials Cardiovasc Med (2002) 1.13
Morning surge in blood pressure. Circulation (2003) 1.12
Disparity implications of Medicare eligibility criteria for medication therapy management services. Health Serv Res (2010) 1.09
Random thoughts on guidelines: how are they determined? are they followed? J Clin Hypertens (Greenwich) (2004) 1.06
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) (2005) 1.02
Hypertension in adults across age groups. JAMA (2005) 0.96
Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich) (2012) 0.95
Hypertension control among newly treated patients before and after publication of the main ALLHAT results and JNC 7 guidelines. J Clin Hypertens (Greenwich) (2012) 0.95
Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2007) 0.95
Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich) (2006) 0.94
Recent clinical trials: the good, the bad, and the misleading. Hypertension (2008) 0.93
The meaning of ALLHAT. J Hypertens (2003) 0.92
Potential health implications of racial and ethnic disparities in meeting MTM eligibility criteria. Res Social Adm Pharm (2013) 0.91
Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med (2012) 0.91
Beta-blockers in hypertension: adding insult to injury. J Am Coll Cardiol (2008) 0.90
Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex. Hypertension (2013) 0.90
Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation (2002) 0.89
Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc (2006) 0.87
Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project. Clin Trials (2009) 0.86
Chlorthalidone versus hydrochlorothiazide. Ann Intern Med (2013) 0.86
The treatment of hypertension during pregnancy: when should blood pressure medications be started? Curr Cardiol Rep (2013) 0.86
The diastolic J curve: alive and threatening. Hypertension (2011) 0.85
Task Force 5: systemic hypertension. J Am Coll Cardiol (2005) 0.84
The nonpharmacologic treatment of hypertension: how effective is it? An update. J Clin Hypertens (Greenwich) (2007) 0.84
Response to six classes of antihypertensive medications by body mass index in a randomized controlled trial. J Clin Hypertens (Greenwich) (2003) 0.84
New recommendations for treating hypertension in black patients: evidence and/or consensus? Hypertension (2010) 0.83
Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements? Eur Heart J (2012) 0.83
National utilization of antihypertensive medications from 2000 to 2006 in the Veterans Health Administration: focus on thiazide diuretics. J Clin Hypertens (Greenwich) (2008) 0.82
Physician or clinical inertia: what is it? Is it really a problem? And what can be done about it? J Clin Hypertens (Greenwich) (2009) 0.81
Hypertension treatment--a success study. J Clin Hypertens (Greenwich) (2006) 0.79
Are lifestyle interventions in the management of hypertension effective? How long should you wait before starting specific medical therapy? An ongoing debate. J Clin Hypertens (Greenwich) (2005) 0.79
Hypertension treatment guidelines: is it time for an update? J Clin Hypertens (Greenwich) (2007) 0.78
Target organ complications and prognostic significance of alerting reaction: analysis from the Dallas Heart Study. J Hypertens (2016) 0.78
The ASCOT trial: a closer look. J Hypertens (2006) 0.78
Chlorthalidone versus hydrochlorothiazide: a tale of tortoises and a hare. Hypertension (2011) 0.78
Comments on the new AHA recommendations for blood pressure measurement. J Clin Hypertens (Greenwich) (2005) 0.77
Potential Health Implications of Medication Therapy Management Eligibility Criteria in the Patient Protection and Affordable Care Act Across Racial and Ethnic Groups. J Manag Care Spec Pharm (2015) 0.77
No surprises in blood pressure awareness study findings: we can do a better job. Arch Intern Med (2003) 0.77
Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs. either monotherapy: ValVET primary results. J Clin Hypertens (Greenwich) (2011) 0.77
Treatment of hypertension: remaining issues after the Anglo-Scandinavian Cardiac Outcomes Trial. Hypertension (2005) 0.76
The treatment of hypertension in the elderly. J Clin Hypertens (Greenwich) (2008) 0.76
Effective treatment of hypertension without medication: is it possible? J Clin Hypertens (Greenwich) (2004) 0.76
Prehypertension--what is it and should it be treated? J Clin Hypertens (Greenwich) (2006) 0.76
Dietary management in the prevention and treatment of hypertension: does it work? J Clin Hypertens (Greenwich) (2008) 0.76
Commentary on the management of elevated blood pressure in pregnancy. J Clin Hypertens (Greenwich) (2009) 0.76
Exercise and atherosclerosis. Ann Intern Med (2004) 0.75
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: is there a difference in response and any advantage to using them together in the treatment of hypertension? J Clin Hypertens (Greenwich) (2008) 0.75
Hypochondriasis. N Engl J Med (2002) 0.75
Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism. J Hypertens (2006) 0.75
The final nail for sodium reduction. Curr Hypertens Rep (2007) 0.75
Salute to the icons of hypertension. J Clin Hypertens (Greenwich) (2004) 0.75
More about prehypertension. J Clin Hypertens (Greenwich) (2004) 0.75